Last 12 months
Inside the activity.
0 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2015 Filed Apr 28, 2015 23:56 UTC |
HOOPER ANTHONY CEVP, Global Commercial Ops.
|
Tax withholdingCommon Stock | 1,575 | $167.91 | $264,458.25 |
DisclosureSEC source: 0001127602-15-015473 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,334 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,943 RSUs which vest on 4/27/2016; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 520 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2015 Filed Apr 29, 2015 00:06 UTC |
Patton Cynthia MSVP & CCO
|
Tax withholdingCommon Stock | 219 | $167.91 | $36,772.29 |
DisclosureSEC source: 0001127602-15-015479 · form4.xml · nonDerivative · entry 2 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,101 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 408 RSUs which vest on 4/27/2016; 3,632 RSUs which vest in two installments of 1,789 and 1,843 on 10/26/2015 and 10/26/2016, respectively; 1,410 RSUs which vest in two installments of 694 and 716 on 1/28/2016 and 1/28/2017, respectively; 1,092 RSUs which vest in two equal installments of 360 on 1/31/2016 and 1/31/2017 and one installment of 372 on 1/31/2018; and 919 shares that vest in two equal installments of 303 on 1/30/2017 and 1/30/2018 and one installment of 313 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 282 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2015 Filed Apr 29, 2015 00:10 UTC |
Piacquad DavidSVP, Business Development
|
Tax withholdingCommon Stock | 274 | $167.91 | $46,007.34 |
DisclosureSEC source: 0001127602-15-015482 · form4.xml · nonDerivative · entry 4 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,784 F1 · balance_after: These shares include 248 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 27, 2015 Filed Apr 29, 2015 00:14 UTC |
SCOTT DAVID JSVP, Gen. Counsel & Secy.
|
Tax withholdingCommon Stock | 1,069 | $167.91 | $179,495.79 |
DisclosureSEC source: 0001127602-15-015486 · form4.xml · nonDerivative · entry 2 SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,949 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,088 RSUs which vest on 4/27/2016; 3,601 RSUs which vest in one installment of 1,773 on 1/28/2016 and one installment of 1,828 on 1/28/2017; 3,362 RSUs which vest in two equal installments of 1,109 on 1/31/2016 and 1/31/2017 and one installment of 1,144 on 1/31/2018; and 2,627 RSUS which vest in three annual installments of 866, 867 and 894 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 363 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2015 Filed Apr 29, 2015 00:18 UTC |
Tross Stuart ASVP, Human Resources
|
Tax withholdingCommon Stock | 242 | $167.91 | $40,634.22 |
DisclosureSEC source: 0001127602-15-015489 · form4.xml · nonDerivative · entry 3 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,187 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 449 RSUs which vest on 4/27/2016; 658 RSUs which vest in one installment of 324 on 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 186 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 26, 2015 Filed Apr 29, 2015 00:10 UTC |
Piacquad DavidSVP, Business Development
|
Tax withholdingCommon Stock | 2,497 | $167.91 | $419,271.27 |
DisclosureSEC source: 0001127602-15-015482 · form4.xml · nonDerivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,058 Read SEC document |
| April 26, 2015 Filed Apr 29, 2015 00:10 UTC |
Piacquad DavidSVP, Business Development
|
Tax withholdingCommon Stock | 151 | $167.91 | $25,354.41 |
DisclosureSEC source: 0001127602-15-015482 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,555 Read SEC document |
| April 26, 2015 Filed Apr 29, 2015 00:16 UTC | Tax withholdingCommon Stock | 40 | $167.91 | $6,716.40 |
DisclosureSEC source: 0001127602-15-015488 · form4.xml · nonDerivative · entry 3 Such Annette Louise · CIK 0001635760 · CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,230 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 4,080 RSUs which vest fully on 7/31/2015; 205 RSUs which vest in two installments of 101 and 104 on 4/26/2016 and 4/26/2017, respectively; 291 RSUs which vest in two equal installments of 96 on 4/25/2016 and 4/25/2017 and one installment of 99 on 4/25/2018; 1,991 RSUs which vest in two equal installments of 657 on 8/1/2016 and 8/1/2017 and one installment of 677 on 8/1/2018; 285 RSUs which vest in 2 equal installments of 94 on 4/24/2017 and 4/24/2018 and one installment of 97 on 4/24/2019; and 1,191 RSUs which vest in 2 equal installments of 393 on 4/24/2017 and 4/24/2018 and one installment of 405 on 4/24/2019. Vested RSUs will be paid in shares fo the Companys common stock on a one-to-one basis. F3 · balance_after: These shares include 247 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
|
| April 26, 2015 Filed Apr 29, 2015 00:18 UTC |
Tross Stuart ASVP, Human Resources
|
Tax withholdingCommon Stock | 176 | $167.91 | $29,552.16 |
DisclosureSEC source: 0001127602-15-015489 · form4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,429 Read SEC document |
| April 25, 2015 Filed Apr 28, 2015 23:38 UTC |
Balachandran MadhavanEVP, Operations
|
GiftCommon Stock | 767 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015466 · form4.xml · nonDerivative · entry 3 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 56,136 Read SEC document |
| April 25, 2015 Filed Apr 28, 2015 23:38 UTC |
Balachandran MadhavanEVP, Operations
|
GiftCommon Stock | 767 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015466 · form4.xml · nonDerivative · entry 2 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,269 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| April 25, 2015 Filed Apr 28, 2015 23:38 UTC |
Balachandran MadhavanEVP, Operations
|
Tax withholdingCommon Stock | 763 | $167.91 | $128,115.33 |
DisclosureSEC source: 0001127602-15-015466 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,036 Read SEC document |
| April 25, 2015 Filed Apr 28, 2015 23:59 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 3,726 | $167.91 | $625,632.66 |
DisclosureSEC source: 0001127602-15-015467 · form4.xml · nonDerivative · entry 1 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,128 Read SEC document |
| April 25, 2015 Filed Apr 28, 2015 23:58 UTC |
Harper Sean EEVP, Research & Development
|
Tax withholdingCommon Stock | 1,065 | $167.91 | $178,824.15 |
DisclosureSEC source: 0001127602-15-015472 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,855 Read SEC document |
| April 25, 2015 Filed Apr 29, 2015 00:03 UTC | Tax withholdingCommon Stock | 1,271 | $167.91 | $213,413.61 |
DisclosureSEC source: 0001127602-15-015476 · form4.xml · nonDerivative · entry 1 MCNAMEE BRIAN M · CIK 0001183885 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,681 Read SEC document |
|
| April 25, 2015 Filed Apr 29, 2015 00:06 UTC |
Patton Cynthia MSVP & CCO
|
Tax withholdingCommon Stock | 266 | $167.91 | $44,664.06 |
DisclosureSEC source: 0001127602-15-015479 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,320 Read SEC document |
| April 25, 2015 Filed Apr 29, 2015 00:10 UTC |
Piacquad DavidSVP, Business Development
|
Tax withholdingCommon Stock | 330 | $167.91 | $55,410.30 |
DisclosureSEC source: 0001127602-15-015482 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,706 Read SEC document |
| April 25, 2015 Filed Apr 29, 2015 00:14 UTC |
SCOTT DAVID JSVP, Gen. Counsel & Secy.
|
Tax withholdingCommon Stock | 1,898 | $167.91 | $318,693.18 |
DisclosureSEC source: 0001127602-15-015486 · form4.xml · nonDerivative · entry 1 SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,018 Read SEC document |
| April 25, 2015 Filed Apr 29, 2015 00:18 UTC |
Tross Stuart ASVP, Human Resources
|
Tax withholdingCommon Stock | 318 | $167.91 | $53,395.38 |
DisclosureSEC source: 0001127602-15-015489 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,605 Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 22:44 UTC |
BALTIMORE DAVIDDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015443 · form4.xml · nonDerivative · entry 1 BALTIMORE DAVID · CIK 0001185858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,350 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 22:47 UTC |
BIONDI FRANKDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015446 · form4.xml · nonDerivative · entry 1 BIONDI FRANK · CIK 0001032669 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,283 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 869 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 22:50 UTC |
COFFMAN VANCE DDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015447 · form4.xml · nonDerivative · entry 1 COFFMAN VANCE D · CIK 0001193998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,319 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 508 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 22:54 UTC |
de Carbonnel FrancoisDirector
|
Tax withholdingCommon Stock | 228 | $167.19 | $38,119.32 |
DisclosureSEC source: 0001127602-15-015449 · form4.xml · nonDerivative · entry 2 de Carbonnel Francois · CIK 0001447121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,139 F1 · balance_after: These shares include 143 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 22:54 UTC |
de Carbonnel FrancoisDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015449 · form4.xml · nonDerivative · entry 1 de Carbonnel Francois · CIK 0001447121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,367 Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 23:00 UTC |
Garland Greg C.Director
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015451 · form4.xml · nonDerivative · entry 1 Garland Greg C. · CIK 0001503107 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,415 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested imediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 23:04 UTC |
ECKERT ROBERTDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015453 · form4.xml · nonDerivative · entry 1 ECKERT ROBERT · CIK 0001194256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,932 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 101 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 23:07 UTC |
HENDERSON REBECCA MDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015454 · form4.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,698 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 328 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 23:18 UTC |
HERRINGER FRANK CDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015457 · form4.xml · nonDerivative · entry 1 HERRINGER FRANK C · CIK 0001171694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,334 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 966 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 23:21 UTC |
Jacks TylerDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015458 · form4.xml · nonDerivative · entry 1 Jacks Tyler · CIK 0001464237 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,909 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Plan) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 33 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 23:23 UTC |
PELHAM JUDITH CDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015459 · form4.xml · nonDerivative · entry 1 PELHAM JUDITH C · CIK 0001185287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,925 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's Common Stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 23:30 UTC |
SUGAR RONALD DDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015464 · form4.xml · nonDerivative · entry 1 SUGAR RONALD D · CIK 0001216519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,337 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 283 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 23:32 UTC |
Williams R SandersDirector
|
GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015465 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| April 24, 2015 Filed Apr 29, 2015 00:16 UTC | GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015488 · form4.xml · nonDerivative · entry 2 Such Annette Louise · CIK 0001635760 · CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,270 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/24/2017, 4/24/2018 and 4/24/2019, respectively. Read SEC document |
|
| April 24, 2015 Filed Apr 29, 2015 00:16 UTC | GrantCommon Stock | 285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-015488 · form4.xml · nonDerivative · entry 1 Such Annette Louise · CIK 0001635760 · CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,079 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/24/2017, 4/24/2018 and 4/24/2019, respectively. Read SEC document |
|
| April 23, 2015 Filed Apr 24, 2015 20:53 UTC |
Tross Stuart ASVP, Human Resources
|
SaleCommon Stock | 3,012 | $169.31 | $509,963.83 |
DisclosureSEC source: 0001127602-15-015086 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,923 F1 · price: The price reported is an average price. The prices ranged from $169.355 to $169.22 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 221 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 22, 2015 Filed Apr 23, 2015 21:04 UTC |
Harper Sean EEVP, Research & Development
|
SaleCommon Stock | 28,000 | $171.58 | $4,804,240.00 |
DisclosureSEC source: 0001127602-15-015038 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,920 F1 · price: The price reported is an average price. The prices ranged from $171.52 to $171.84 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,040 RSUs which vest in one installment of 2,040 on 4/25/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 3,940 RSUs which vest in two equal installments of 1,300 on 1/30/2017 and 1/30/2018 and one installment of 1,340 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 677 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 22:43 UTC |
Balachandran MadhavanEVP, Operations
|
GiftCommon Stock | 7,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-012977 · form4.xml · nonDerivative · entry 3 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 55,369 Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 22:43 UTC |
Balachandran MadhavanEVP, Operations
|
GiftCommon Stock | 7,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-012977 · form4.xml · nonDerivative · entry 2 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,799 F1 · kind: These shares are being transferred to the reporting person's Family Trust. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,530 RSUs which vest in one installment on 4/25/2015; 1,684 RSUs which vest in two installments of 829 and 855 on 4/27/2015 and 4/27/2016, respectively; 17,845 RSUs which vest in one installment of 8,789 on 7/31/2015 and one installment of 9,056 on 7/31/2016; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 4,707 RSUs which vest in two equal installments of 1,553 each on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018; and 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,346 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 22:43 UTC |
Balachandran MadhavanEVP, Operations
|
Tax withholdingCommon Stock | 8,311 | $160.55 | $1,334,331.05 |
DisclosureSEC source: 0001127602-15-012977 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,413 Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 22:45 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 69,253 | $160.55 | $11,118,569.15 |
DisclosureSEC source: 0001127602-15-012978 · form4.xml · nonDerivative · entry 1 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,854 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 7,140 RSUs which vest in one installment on 4/25/2015; 14,029 RSUs which vest in two installments of 6,910 and 7,119 on 4/27/2015 and 4/27/2016, respectively; 12,525 RSUs which vest in two installments of 6,169 and 6,356 on 1/28/2016 and 1/28/2017, respectively; 15,132 RSUs which vest in three installments of 4,993, 4,994 and 5,145 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 13,398 shares which vest in two equal installments of 4,421 on 1/30/2017 and 1/30/2018 and one installment of 4,556 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,745 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 22:47 UTC |
Harper Sean EEVP, Research & Development
|
Tax withholdingCommon Stock | 28,624 | $160.55 | $4,595,583.20 |
DisclosureSEC source: 0001127602-15-012981 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,920 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,040 RSUs which vest in one installment of 2,040 on 4/25/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 3,940 RSUs which vest in two equal installments of 1,300 on 1/30/2017 and 1/30/2018 and one installment of 1,340 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 677 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 22:49 UTC |
HOOPER ANTHONY CEVP, Global Commercial Ops.
|
Tax withholdingCommon Stock | 28,624 | $160.55 | $4,595,583.20 |
DisclosureSEC source: 0001127602-15-012982 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,909 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 680 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 22:54 UTC | Tax withholdingCommon Stock | 14,517 | $160.55 | $2,330,704.35 |
DisclosureSEC source: 0001127602-15-012983 · form4.xml · nonDerivative · entry 1 MCNAMEE BRIAN M · CIK 0001183885 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,952 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,550 RSUs which vest in one installment of 2,550 on 4/25/2015; 2,993 RSUs which vest in two annual installments of 1,474 and 1,519 on 4/27/2015 and 4/27/2016, respectively; 2,975 RSUs which vest in two installments of 1,465 and 1,510 on 1/28/2016 and 1/28/2017, respectively; 7,488 RSUs which vest in one installment of 3,688 on 10/25/2015 and one installment of 3,800 on 10/25/2016; 4,707 RSUs which vest in two equal installments of 1,553 on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018; and 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 631 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
|
| March 27, 2015 Filed Mar 31, 2015 22:57 UTC |
Patton Cynthia MSVP & CCO
|
Tax withholdingCommon Stock | 3,500 | $160.55 | $561,925.00 |
DisclosureSEC source: 0001127602-15-012984 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,586 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 508 RSUs which vest on 4/25/2015; 804 RSUs which vest in two annual installments of 396 on 4/27/2015 and 408 on 4/27/2016; 3,632 RSUs which vest in two installments of 1,789 and 1,843 on 10/26/2015 and 10/26/2016, respectively; 1,410 RSUs which vest in two installments of 694 and 716 on 1/28/2016 and 1/28/2017, respectively; 1,092 RSUs which vest in two equal installments of 360 on 1/31/2016 and 1/31/2017 and one installment of 372 on 1/31/2018; and 919 shares that vest in two equal installments of 303 on 1/30/2017 and 1/30/2018 and one installment of 313 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 304 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 22:59 UTC |
Piacquad DavidSVP, Business Development
|
Tax withholdingCommon Stock | 4,402 | $160.55 | $706,741.10 |
DisclosureSEC source: 0001127602-15-012985 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,036 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 632 RSUs which fully vest on 4/25/2015; 1,005 RSUs which vest in two annual installments of 495 on 4/27/2015 and 510 on 4/27/2016; 840 RSUs which vest in two equal installments of 277 each on 4/26/2015 and 4/26/2016 and one installment of 286 on 4/26/2017; 9,226 RSUs which vest in two equal installments of 4,613 each on 4/26/2015 and 4/26/2017; 1,166 RSUs which vest in annual installments of 384, 385 and 397 on 4/25/2016, 4/25/2017 and 4/25/2018, respectively; and 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 455 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 23:02 UTC |
SCOTT DAVID JSVP, Gen. Counsel & Secy.
|
Tax withholdingCommon Stock | 20,314 | $160.55 | $3,261,412.70 |
DisclosureSEC source: 0001127602-15-012986 · form4.xml · nonDerivative · entry 1 SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,916 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,808 RSUs which vest in one installment on 4/25/2015; 4,115 RSUs which vest in two annual installments of 2,027 and 2,088 on 4/27/2015 and 4/27/2016, respectively; 3,601 RSUs which vest in one installment of 1,773 on 1/28/2016 and one installment of 1,828 on 1/28/2017; 3,362 RSUs which vest in two equal installments of 1,109 on 1/31/2016 and 1/31/2017 and one installment of 1,144 on 1/31/2018; and 2,627 RSUS which vest in three annual installments of 866, 867 and 894 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 477 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 23:05 UTC |
Tross Stuart ASVP, Human Resources
|
Tax withholdingCommon Stock | 3,711 | $160.55 | $595,801.05 |
DisclosureSEC source: 0001127602-15-012987 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,935 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 221 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 11, 2015 Filed Mar 13, 2015 22:32 UTC |
HOOPER ANTHONY CEVP, Global Commercial Ops.
|
Tax withholdingCommon Stock | 27,540 | $153.58 | $4,229,593.20 |
DisclosureSEC source: 0001127602-15-011303 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,148 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 573 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 04, 2015 Filed Mar 7, 2015 01:57 UTC |
Balachandran MadhavanEVP, Operations
|
GrantCommon Stock | 15,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010542 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,352 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,530 RSUs which vest in one installment on 4/25/2015; 1,684 RSUs which vest in two installments of 829 and 855 on 4/27/2015 and 4/27/2016, respectively; 17,845 RSUs which vest in one installment of 8,789 on 7/31/2015 and one installment of 9,056 on 7/31/2016; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 4,707 RSUs which vest in two equal installments of 1,553 each on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018; and 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,054 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 04, 2015 Filed Mar 7, 2015 01:59 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
GrantCommon Stock | 132,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010543 · form4.xml · nonDerivative · entry 1 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,147 F1 · security: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 7,140 RSUs which vest in one installment on 4/25/2015; 14,029 RSUs which vest in two installments of 6,910 and 7,119 on 4/27/2015 and 4/27/2016, respectively; 12,525 RSUs which vest in two installments of 6,169 and 6,356 on 1/28/2016 and 1/28/2017, respectively; 15,132 RSUs which vest in three installments of 4,993, 4,994 and 5,145 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 13,398 shares which vest in two equal installments of 4,421 on 1/30/2017 and 1/30/2018 and one installment of 4,556 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 7,140 RSUs which vest in one installment on 4/25/2015; 14,029 RSUs which vest in two installments of 6,910 and 7,119 on 4/27/2015 and 4/27/2016, respectively; 12,525 RSUs which vest in two installments of 6,169 and 6,356 on 1/28/2016 and 1/28/2017, respectively; 15,132 RSUs which vest in three installments of 4,993, 4,994 and 5,145 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 13,398 shares which vest in two equal installments of 4,421 on 1/30/2017 and 1/30/2018 and one installment of 4,556 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,458 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.